In a noteworthy move this month, the Drug Enforcement Administration (DEA), in collaboration with the Substance Abuse and Mental Health Services Administration (SAMHSA), promulgated a Second Temporary Rule. This rule continues the extension of telemedicine waivers of the Ryan Haight Act (RHA) during the ongoing COVID-19 Public Health Emergency (PHE). Initially, the rule, which enables increased tele-prescribing flexibilities, was slated to lapse on November 11, 2023. However, with the new mandate, these allowances will now be upheld until December 31, 2024.
The Ryan Haight Act, enacted in 2008, put in place strict guidelines on prescribing controlled substances via the internet, with a specific focus on preventing online pharmacies’ abuse. The triggered changes under the COVID-19 PHE allowed for a more lenient interpretation of these rules, catering to the unprecedented demands of the pandemic era where telehealth services have proven crucial.
This most recent action represents the second extension of tele-prescribing flexibilities since the onset of the pandemic, highlighting the persistent importance of digital health services in maintaining public health during these challenging times. The extension bears significant implications for both patients and healthcare providers alike, offering continued access to the necessary care and medicines required through remote, online consultations.
However, it’s important to note that while the extended allowances are beneficial for the present context, there is yet to be seen whether such relaxations will remain in place post pandemic or more permanent regulations will be enacted.
The full details about the Second Temporary Rule can be found on the DEA’s official document posted on JDSupra.com.